Virttu Biologics Appoints CEO
This article was originally published in Scrip
Executive Summary
Virttu Biologics, a biotechnology company focused on developing oncolytic immunotherapies, has appointed Deirdre Y. Gillespie CEO. Gillespie has experience of working with oncolytic vectors and was CEO of privately held Oxxon Therapeutics Inc. from 2001 to 2006. She was previously president and CEO of publically held La Jolla Pharmaceutical Company and chief operating officer of Vical, Inc. Gillespie also held various positions in clinical development at Sandoz Pharma AG (Novartis) and senior strategic and commercial positions at DuPont Merck Pharmaceutical Company including vice-president of marketing.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.